Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Crucell N.V. (CRXL) -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (531)	1/26/2009 7:44:05 AM
From: kenhott	Read Replies (2) \| Respond to of 560

PFE takes out WYE and WYE drops the fishing line to CRXL. Looks like the WYE team will be out but I expect PFE to keep the vaccine business as it is a key part of the acquisition. Everything else like consumer, etc. will probably go after a time. A major part of the deal is the cost savings which will eat up a lot of attention. I am looking to get back in CRXL if the shares get overly hit. In my opinion it is in play and there are others who will take a run at CRXL. Even thought PFE will probably keep the vaccine business, forget about PFE because they will be focused elsewhere for a good while.